Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

IMPORTANCE: There are no specifically approved targeted therapies for the most common genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung cancer. OBJECTIVE: To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA
Main Authors: Jänne, Pasi A., van den Heuvel, Michel M., Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crinò, Lucio, Orlov, Sergey, Blackhall, Fiona, Wolf, Juergen, Garrido, Pilar, Poltoratskiy, Artem, Mariani, Gabriella, Ghiorghiu, Dana, Kilgour, Elaine, Smith, Paul, Kohlmann, Alexander, Carlile, David J., Lawrence, David, Bowen, Karin, Vansteenkiste, Johan
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2017
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815037/
https://ncbi.nlm.nih.gov/pubmed/28492898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2017.3438
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares